Filing Analysis
Senseonics Holdings, Inc. has filed an 8-K to announce its financial results for the quarter ended June 30, 2026. The filing serves as a cover sheet for the press release containing the company's quarterly earnings and corporate outlook.
📋 Key Facts
- The filing reports on the quarter ended June 30, 2026.
- Company issued a press release (Exhibit 99.1) regarding financial results and corporate highlights.
- A conference call was scheduled to discuss the quarterly results and outlook.
Senseonics Holdings, Inc. filed an 8-K to announce its quarterly financial results for the period ending September 30, 2025. The filing serves as a formal notice that a press release containing these results has been issued.
📋 Key Facts
- Reporting date: November 5, 2025
- Period covered: Quarter ended September 30, 2025
- The company announced a conference call to discuss financial results and corporate highlights/outlook.
Senseonics Holdings, Inc. has filed a Certificate of Amendment to implement a 1-for-20 reverse stock split effective October 17, 2025. This action includes a proportional reduction in authorized shares from 1.4 billion to 70 million.
🚩 Red Flags
- Reverse stock split (often used to prevent delisting or improve share price perception).
- Significant reduction in authorized shares (70M vs 1.4B) suggests a massive restructuring of the capital base.
📋 Key Facts
- Reverse stock split ratio is one-for-twenty (1-for-20).
- Effective date of the Amendment: October 17, 2025, at 4:05 p.m. ET.
- Authorized shares reduced from 1,400,000,000 to 70,000,000.
- New CUSIP number for common stock: 81727U303.
- Trading on NYSE American is expected to resume on an adjusted basis on October 20, 2025.
- No fractional shares will be issued; cash payments will be made in lieu of fractions.
Senseonics Holdings, Inc. issued a press release providing preliminary unaudited financial results for the third quarter of 2025. The company reports significant year-over-year revenue growth driven by strong new patient acquisition in the U.S.
🚩 Red Flags
- Information is preliminary, unaudited, and based on management estimates rather than reviewed financial statements.
📋 Key Facts
- Preliminary unaudited revenue for Q3 2025 is approximately $8.1 million.
- Revenue represents a 91% increase compared to Q3 2024.
- U.S. new patient growth increased by approximately 160% year-over-year.
- Financial results are subject to change pending finalization and audit.
Senseonics Holdings, Inc. issued an 8-K to announce preliminary, unaudited financial information for the quarter ended September 30, 2025, via a press release.
📋 Key Facts
- The filing was made on October 6, 2025.
- Includes business updates and preliminary, unaudited financial results for Q3 2025 (ended Sept 30, 2025).
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability.
Senseonics Holdings, Inc. held a special meeting of stockholders on September 29, 2025, where shareholders approved a proposal to implement a reverse stock split.
🚩 Red Flags
- Approval of a reverse stock split is often used to combat delisting notices due to low share price.
- Significant opposition from shareholders (over 178 million votes against).
📋 Key Facts
- Stockholders approved a series of alternate amendments to the Certificate of Incorporation.
- The proposed reverse stock split range is between 1-for-10 and 1-for-20.
- The Board of Directors has sole discretion to determine the final ratio at any time prior to September 29, 2026.
- Voting results: 285,639,190 votes For; 178,232,358 votes Against; 5,014,498 Abstentions.
Senseonics Holdings entered into an amended loan agreement providing up to $100 million in senior secured term loans, including a $35 million initial tranche used to refinance existing debt. The company also signed an MOU with Ascensia Diabetes Care to reclaim commercial operations for the Eversense product and appointed Brian Hansen as Chief Commercial Officer effective January 2026.
🚩 Red Flags
- High interest rate environment for debt (floor of 9.90%).
- Significant dilution risk via warrants with a low exercise price ($0.4545) and additional warrants tied to future tranches.
- Performance-based covenants starting in 2026 create pressure on revenue targets to avoid default.
- The refinancing of existing debt suggests ongoing liquidity management needs.
📋 Key Facts
- Amended Loan Agreement provides up to $100 million in senior secured term loans (initial $35M funded on Sept 3, 2025).
- Loan maturity date is September 3, 2029.
- Interest rate: Greater of WSJ Prime + 2.40% or 9.90%.
- Includes a minimum cash covenant and a performance covenant (net product revenue) starting Jan 1, 2026.
- Existing warrants were amended with an exercise price reduction to $0.4545 per share; additional warrants will be issued upon funding subsequent tranches.
- MOU signed with Ascensia Diabetes Care Holdings AG to transfer Eversense commercial operations back to Senseonics by Jan 1, 2026.
- Brian Hansen (current Director and President of CGM at Ascensia) appointed as CCO effective Jan 1, 2026.
Senseonics Holdings, Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2025. The filing serves as a formal notice that a press release containing these results and corporate outlook has been issued.
📋 Key Facts
- Report date: August 6, 2025
- Reporting period: Quarter ended June 30, 2025
- The company announced financial results via a press release (Exhibit 99.1).
- A conference call was scheduled to discuss quarterly results and corporate highlights.
Senseonics Holdings, Inc. reported the results of its Annual Meeting held on May 21, 2025. Stockholders approved all three proposals, including the election of four directors and the ratification of KPMG LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on May 21, 2025.
- Total shares outstanding at record date: 654,216,092.
- Quorum reached with 351,668,117 shares (53.75%) present or represented by proxy.
- Four nominees—Stephen P. DeFalco, Brian Hansen, Douglas S. Prince, and Douglas A. Roeder—were all elected to the Board of Directors.
- Advisory vote on executive compensation was approved with 154,434,501 votes in favor.
- KPMG LLP was ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
This is an Amendment No. 1 to a previously filed Form 8-K, specifically intended to amend and restate Exhibit 5.1 (Legal Opinion) and Exhibit 23.1 (Consent of Counsel). The filing serves as a technical correction or update to legal documentation provided by Cooley LLP.
🚩 Red Flags
- None identified; this appears to be a routine administrative amendment to legal exhibits.
📋 Key Facts
- The filing is an Amendment No. 1 to the Original Report filed on May 16, 2025.
- Purpose: To amend and restate Exhibit 5.1 (Opinion of Cooley LLP) and Exhibit 23.1 (Consent of Cooley LLP).
- No other information in the original report is being amended.
- Signed by Rick Sullivan, Chief Financial Officer, on May 19, 2025.
Senseonics Holdings, Inc. entered into an underwriting agreement to issue and sell 100,000,000 shares of common stock at $0.50 per share. The offering is expected to yield approximately $45.4 million in net proceeds and is scheduled to close on May 19, 2025.
🚩 Red Flags
- Significant dilution: Issuing 100 million shares at $0.50 per share represents massive equity dilution for existing shareholders.
- Low share price: The $0.50 offering price is extremely low, often characteristic of companies facing liquidity constraints or struggling to maintain minimum exchange requirements.
📋 Key Facts
- Total shares to be issued: 100,000,000 common shares.
- Offering price per share: $0.50.
- Underwriters include TD Securities (USA) LLC and Barclays Capital Inc.
- Expected net proceeds: ~$45,400,000 (or ~$52,450,000 if underwriters exercise the over-allotment option).
- Over-allotment option: Up to 15,000,000 additional shares.
- Expected closing date: May 19, 2025.
- The offering is being conducted via a shelf registration statement on Form S-3.
Senseonics Holdings entered into a securities purchase agreement with Abbott Laboratories for a private placement of up to $25 million in common stock. The agreement includes significant strategic rights granted to Abbott, including an exclusive negotiation period regarding potential mergers, acquisitions, or material asset/IP licenses.
🚩 Red Flags
- Significant 'Right of First Refusal/Negotiation' style clause: Abbott has an exclusive period to negotiate strategic transactions (M&A or IP licensing), which could act as a poison pill or deterrent to other potential acquirers.
- Termination of existing equity distribution agreement with Goldman Sachs suggests a shift in capital raising strategy or preference for the Abbott partnership.
📋 Key Facts
- Private placement of up to $25 million in common stock to Abbott Laboratories.
- Abbott's ownership is capped at 4.99% of the Company's Common Stock following the offering.
- The purchase price per share will equal the public offering price in a concurrent proposed public offering.
- Abbott receives information rights regarding clinical and regulatory progress of Gemini and Freedom products.
- Abbott is granted an exclusive negotiation period for strategic transactions (merger, acquisition, or material asset/IP sale) until the earlier of: 90 days after FDA clearance of Freedom as an iCGM, Dec 31, 2032, or if Abbott's ownership drops below 80% of its purchased shares.
- The Company terminated its equity distribution agreement with Goldman Sachs & Co. LLC on May 15, 2025.
Senseonics Holdings, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025. The filing serves as a formal announcement of the earnings release and scheduled conference call.
📋 Key Facts
- Report date: May 8, 2025
- Reporting period: Quarter ended March 31, 2025
- The company issued a press release (Exhibit 99.1) containing financial results and corporate outlook.
- A conference call was scheduled to discuss the quarterly results and recent highlights.
Senseonics Holdings, Inc. filed an 8-K to announce its financial results for the quarter ended December 31, 2024 and to provide information regarding a conference call to discuss corporate highlights and outlook.
📋 Key Facts
- Reporting period: Quarter ended December 31, 2024.
- Filing date: March 3, 2025.
- The company issued a press release (Exhibit 99.1) containing financial results and corporate highlights.
- A conference call is scheduled to discuss the quarterly results and outlook.
Senseonics Holdings, Inc. announced the resignation of Anthony Raab from its Board of Directors, effective January 17, 2025.
📋 Key Facts
- Anthony Raab resigned from the Board of Directors on January 17, 2025.
- The resignation is intended to allow Mr. Raab to focus on his professional investment career, other board roles, and family commitments.
- The company explicitly stated that the resignation was not due to any disagreements with the Company, management, or Board regarding operations, policies, or practices.
Senseonics Holdings announced the cancellation of a special meeting intended to seek stockholder approval for a significant reverse stock split (25:1 to 50:1) and provided preliminary unaudited financial results for FY2024.
🚩 Red Flags
- Cancellation of a reverse stock split meeting (indicates failure to secure shareholder support or strategic pivot regarding the split).
- Proposed reverse split range of 25:1 to 50:1 is highly aggressive, typically used to combat extreme low share prices/delisting risks.
📋 Key Facts
- Company cancelled the Special Meeting of Stockholders scheduled for January 10, 2025 regarding a proposed reverse stock split in the range of 25:1 to 50:1.
- Preliminary unaudited revenue for Q4 2024 was approximately $8.3 million.
- Preliminary unaudited revenue for full year 2024 was approximately $22.5 million.
- Expected cash, cash equivalents, and restricted cash as of Dec 31, 2024, is approximately $74.9 million.
- Patient base grew 56% in 2024 to approximately 6,000 global patients.
Senseonics Holdings, Inc. provided an update regarding its participation in the Stifel 2024 Healthcare Conference and updated its corporate presentation. The filing is a routine disclosure of non-material information under Item 7.01.
📋 Key Facts
- Management presented at the Stifel 2024 Healthcare Conference on November 19, 2024.
- The Company updated its corporate presentation.
- An archive of the conference presentation is available on the Company's Investor Relations website.
Senseonics Holdings, Inc. issued an 8-K to announce its financial results for the quarter ended September 30, 2024 and scheduled a conference call to discuss corporate highlights.
📋 Key Facts
- Report date: November 7, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes the announcement of financial results via press release (Exhibit 99.1).
- A conference call was scheduled to discuss results and corporate outlook.
Senseonics Holdings, Inc. announced a significant registered direct offering and private placement of warrants to raise approximately $16 million in gross proceeds. The company also amended its existing equity distribution agreement with Goldman Sachs to increase the total capacity to $55 million.
🚩 Red Flags
- Significant dilution: The offering involves over 45 million new shares at a low price point ($0.35).
- Warrant overhang: Issuance of warrants equal to the number of shares sold creates significant future dilution.
- Debt repayment use of proceeds: A portion of the capital is earmarked for repaying convertible notes rather than purely R&D or growth.
📋 Key Facts
- Registered Direct Offering: 45,714,286 shares at $0.35 per share (combined with warrants).
- Private Placement: 45,714,286 warrants to purchase common stock at an exercise price of $0.35.
- Expected gross proceeds from the offering: ~$16 million (excluding potential $16 million from warrant exercises).
- Warrants are non-exercisable for the first six months and expire in five years.
- Amendment to Equity Distribution Agreement with Goldman Sachs increases total capacity to $55 million.
- Use of proceeds includes working capital and repayment of 5.25% Convertible Senior Notes due 2025.
Senseonics Holdings, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a vehicle to furnish the press release containing these results and upcoming conference call details.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial results and corporate highlights.
- A conference call is scheduled to discuss the quarterly results and company outlook.
Senseonics Holdings, Inc. issued an 8-K to furnish a press release regarding its 2024 business outlook and financial guidance. The filing serves as a regulatory vehicle to communicate updated company expectations to the market.
📋 Key Facts
- The filing was made on June 21, 2024.
- The primary purpose is to provide a 'Business Update and Full Year 2024 Financial Outlook'.
- Information is provided under Item 7.01 (Regulation FD Disclosure).
- The press release is furnished as Exhibit 99.1.
Senseonics Holdings, Inc. held its 2024 Annual Meeting of Stockholders on May 22, 2024, where shareholders approved a significant increase in authorized common stock and elected three directors.
🚩 Red Flags
- Significant opposition to the share authorization increase (approximately 27% of voting shares cast 'Against' Proposal No. 4).
📋 Key Facts
- Stockholders approved an amendment to increase authorized common stock from 900,000,000 to 1,400,000,000 shares.
- Three nominees (Steven Edelman, Edward J. Fiorentino, and Anthony Raab) were elected to the Board of Directors until 2027.
- KPMG LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
- Shareholder quorum at the meeting was 52.83% (280,412,742 shares present/represented out of 530,817,549 outstanding).
- The amendment to increase authorized shares passed with 155,991,595 votes in favor and 119,606,483 against.
Senseonics Holdings, Inc. issued an 8-K to announce its financial results for the quarter ended March 31, 2024. The filing serves as a vehicle to furnish their quarterly earnings press release and schedule a conference call to discuss corporate highlights.
📋 Key Facts
- Report date: May 13, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes Exhibit 99.1 (Press Release) regarding financial results and outlook.
- Company is listed on the NYSE American under ticker SENS.
Senseonics Holdings, Inc. announced the resignation of director Robert Schumm and the appointment of Brian Hansen to the Board of Directors. The change is a result of internal restructuring at PHC Holdings Corporation (the company's major partner/investor) rather than any disagreement with Senseonics management.
🚩 Red Flags
- High revenue concentration: 93% of FY2023 net revenues are derived from the distribution arrangement with Ascensia/PHC-related entities.
📋 Key Facts
- Robert Schumm resigned from the Board effective March 19, 2024.
- Brian Hansen appointed to the Board as a Class III director; term expires at 2025 annual meeting.
- Mr. Hansen is the President of CGM at Ascensia Diabetes Care Holding AG (a PHC subsidiary).
- Ascensia's distribution arrangement accounted for 93% of total net revenues for FY2023.
- The change follows a shift in oversight roles within PHC Holdings Corporation.
Senseonics Holdings, Inc. issued an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023. The filing serves as a vehicle to furnish their earnings press release (Exhibit 99.1) to the SEC.
📋 Key Facts
- Report date: February 29, 2024
- Reporting period: Quarter and year ended December 31, 2023
- The filing includes a press release regarding financial results and corporate highlights (Exhibit 99.1)
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability.
Senseonics Holdings, Inc. announced the funding of a $10.0 million Tranche 2 Loan as part of an existing $50.0 million senior secured term loan facility. This disbursement follows the company's satisfaction of specific terms and conditions during Q4 2023.
🚩 Red Flags
- The company is utilizing a debt-heavy structure (senior secured term loans) to fund operations, which is common in micro-cap medtech but increases leverage risk.
📋 Key Facts
- The funding amount is $10.0 million for Tranche 2 of a larger credit facility.
- The total available senior secured term loan facility is up to $50.0 million.
- Initial term loan of $25.0 million was previously funded on September 8, 2023.
- Lenders include Hercules Capital, Inc. acting as administrative and collateral agent.
- Funding occurred on January 2, 2024, following satisfaction of Q4 2023 conditions.